Metastatic colorectal cancer, first line
Must Be Really Sure before cycle 1
Algorithm
Doublet = FOLFOX or FOLFIRI · Triplet = FOLFOXIRI · EGFR (epidermal growth factor receptor) antibody = cetuximab, panitumumab
Median months, new regimen in blue
KEYNOTE-177 · mismatch repair deficient · months without progression
BREAKWATER · BRAF V600E · months alive
PARADIGM · RAS wild type, left side · months alive
- DPYD makes the enzyme that clears fluorouracil. Capecitabine counts too.
- FDA boxed warning, Feb 2026: test before cycle 1.
- Early severe toxicity: uridine triacetate within 96 hours.
Sources
Retrieved from PubMed and the FDA, checked Nov 20, 2026.
- André T, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer (KEYNOTE-177). N Engl J Med 2020. PubMed 33264544 · doi:10.1056/NEJMoa2017699
- Elez E, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer (BREAKWATER). N Engl J Med 2025. PubMed 40444708 · doi:10.1056/NEJMoa2501912
- Watanabe J, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer (PARADIGM). JAMA 2023. PubMed 37071094 · doi:10.1001/jama.2023.4428
- Cremolini C, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab (TRIBE2). Lancet Oncol 2020. PubMed 32164906 · doi:10.1016/S1470-2045(19)30862-9
- Amstutz U, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018, with the November 2018 online update. PubMed 29152729 · doi:10.1002/cpt.911
- Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018. Half dose was adequate for the two most severe variants; a 25% reduction was not enough for the two milder ones. PubMed 30348537 · doi:10.1016/S1470-2045(18)30686-7
- Ison G, et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities. Clin Cancer Res 2016. PubMed 27401247 · doi:10.1158/1078-0432.CCR-16-0638
- FDA. Safety labeling update for capecitabine and fluorouracil: risks associated with dihydropyrimidine dehydrogenase deficiency. Communication of Feb 5, 2026. fda.gov
Penile cancer, positive nodes
Clinical node category (cN): groin exam plus imaging
p16 = the stain that stands in for HPV (human papillomavirus). Positive = better prognosis.
Algorithm
EAU-ASCO 2023 rates chemotherapy first as a weak recommendation; randomized answer (InPACT) pending.
TIP before surgery: 30 men
Phase II, single arm (Pagliaro, J Clin Oncol 2010). cN2 or cN3.
TIP: 4 cycles, every 3 to 4 weeks
All three hit the marrow: consider growth factor from cycle 1.
Boosters and TIP
Fixed, Bulky, Bilateral or Pelvic: TIP before the knife.
Sources
Retrieved from PubMed, ClinicalTrials.gov and the EAU-ASCO recommendation table, checked Nov 20, 2026.
- Pagliaro LC, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010. PubMed 20625118 · doi:10.1200/JCO.2010.29.5477
- Brouwer OR, et al. European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update. Eur Urol 2023. PubMed 36906413 · doi:10.1016/j.eururo.2023.02.027
- NCCN Guidelines: Penile Cancer (4 cm node size cutoff), current version.
- Mustasam A, et al. The prognostic role of HPV or p16INK4a status in penile squamous cell carcinoma: a meta-analysis. J Natl Compr Canc Netw 2025. PubMed 39752880 · doi:10.6004/jnccn.2024.7078
- InPACT, NCT02305654: active, not recruiting, no results posted. ClinicalTrials.gov
- David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005. PubMed 15923801 · doi:10.1097/01.coc.0000158439.02724.5a
- Richards A, et al. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity (retrospective; prevention did not lower the rate). J Oncol Pharm Pract 2011. PubMed 20861178 · doi:10.1177/1078155210385159
- Kerbusch T, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin (small study; the booster effect is extrapolated from ketoconazole). Clin Pharmacol Ther 2001. PubMed 11503007 · doi:10.1067/mcp.2001.117283
- Strope JD, et al. Drug-drug interactions in patients with HIV and cancer in Sub-Saharan Africa. AIDS Rev 2020. PubMed 33105469 · doi:10.24875/AIDSRev.20000005
- Branch C, et al. Drug-drug interactions in HIV-infected patients receiving chemotherapy. Expert Opin Drug Metab Toxicol 2025. PubMed 39305240 · doi:10.1080/17425255.2024.2408004